Management of disease- and treatment-related complications in patients with multiple myeloma-Reference-Cited by-同舟云学术

Management of disease- and treatment-related complications in patients with multiple myeloma

Published:2010-05-14 Issue:S1 Volume:27 Page:43-52
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Gay Francesca,Palumbo Antonio

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-010-9542-z.pdf

Reference46 articles.

1. Rajkumar SV, Kyle RA. Plasma Cell Disorders. In: Goldman L, Ausiello D, editors. Cecil textbook of medicine. 23rd ed. Philadelphia: W B Saunders; 2008. p. 1426–37.

2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–73.

3. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33(2):86–9.

4. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26(3):480–92.

5. Palumbo A, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–31.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pentagalloyl Glucose: A Review of Anticancer Properties, Molecular Targets, Mechanisms of Action, Pharmacokinetics, and Safety Profile;Molecules;2023-06-19

2. Preventing osteolytic lesions and osteomyelitis in multiple myeloma;Journal of Bone Oncology;2022-12

3. Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA);Exploratory Research in Clinical and Social Pharmacy;2022-09

4. Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis;PharmacoEconomics - Open;2022-06-24

5. The designed NF‑κB inhibitor, DHMEQ, inhibits KISS1R‑mediated invasion and increases drug‑sensitivity in mouse plasmacytoma SP2/0 cells;Experimental and Therapeutic Medicine;2021-08-02